cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action

SH Francis, JL Busch, JD Corbin - Pharmacological reviews, 2010 - ASPET
To date, studies suggest that biological signaling by nitric oxide (NO) is primarily mediated
by cGMP, which is synthesized by NO-activated guanylyl cyclases and broken down by …

Mammalian cyclic nucleotide phosphodiesterases: molecular mechanisms and physiological functions

SH Francis, MA Blount, JD Corbin - Physiological reviews, 2011 - journals.physiology.org
The superfamily of cyclic nucleotide (cN) phosphodiesterases (PDEs) is comprised of 11
families of enzymes. PDEs break down cAMP and/or cGMP and are major determinants of …

Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives …

T Keravis, C Lugnier - British journal of pharmacology, 2012 - Wiley Online Library
Cyclic nucleotide phosphodiesterases (PDEs) that specifically inactivate the intracellular
messengers cAMP and cGMP in a compartmentalized manner represent an important …

Mechanisms of penile erection and basis for pharmacological treatment of erectile dysfunction

KE Andersson - Pharmacological reviews, 2011 - ASPET
Erection is basically a spinal reflex that can be initiated by recruitment of penile afferents,
both autonomic and somatic, and supraspinal influences from visual, olfactory, and …

The cGMP system: Components and function

F Hofmann - Biological chemistry, 2020 - degruyter.com
The cyclic guanosine monophosphate (cGMP) signaling system is one of the most
prominent regulators of a variety of physiological and pathophysiological processes in many …

Activation of PDE10 and PDE11 phosphodiesterases

R Jäger, C Russwurm, F Schwede, HG Genieser… - Journal of biological …, 2012 - ASBMB
The most recently identified cyclic nucleotide phosphodiesterases, PDE10 and PDE11,
contain a tandem of so-called GAF domains in their N-terminal regulatory regions. In PDE2 …

Pharmacological manipulation of cGMP and NO/cGMP in CNS drug discovery

MA Hollas, MB Aissa, SH Lee, JM Gordon-Blake… - Nitric Oxide, 2019 - Elsevier
The development of small molecule modulators of NO/cGMP signaling for use in the CNS
has lagged far behind the use of such clinical agents in the periphery, despite the central …

Sildenafil potentiates a cGMP-dependent pathway to promote melanoma growth

S Dhayade, S Kaesler, T Sinnberg, H Dobrowinski… - Cell reports, 2016 - cell.com
Sildenafil, an inhibitor of the cGMP-degrading phosphodiesterase 5 that is used to treat
erectile dysfunction, has been linked to an increased risk of melanoma. Here, we have …

Genetic alterations in the NO-cGMP pathway and cardiovascular risk

J Wobst, H Schunkert, T Kessler - Nitric Oxide, 2018 - Elsevier
In the past ten years, several chromosomal loci have been identified by genome-wide
association studies to influence the risk of coronary artery disease (CAD) and its risk factors …

Decreased catalytic activity and altered activation properties of PDE6C mutants associated with autosomal recessive achromatopsia

T Grau, NO Artemyev, T Rosenberg… - Human molecular …, 2011 - academic.oup.com
Mutations in the gene encoding the catalytic subunit of the cone photoreceptor
phosphodiesterase (PDE6C) have been recently reported in patients with autosomal …